Hydroxyprogestérone caproate (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Hydroxyprogestérone caproate" in French language version.

refsWebsite
Global rank French rank
2nd place
3rd place
4th place
12th place
3rd place
11th place
57th place
4th place
447th place
1,409th place
18th place
118th place
5th place
13th place
1st place
1st place
399th place
2,761st place
3,322nd place
7,832nd place
1,824th place
3,436th place
low place
low place
1,226th place
347th place
507th place
420th place
low place
low place
low place
low place
low place
low place
2,769th place
931st place
1,865th place
low place
274th place
223rd place
low place
low place
310th place
936th place
1,697th place
4,059th place

bmj.com

blogs.bmj.com

books.google.com

  • Ovarian Function and its Disorders : Diagnosis and Therapy, Springer Science & Business Media, , 95– (ISBN 978-94-009-8195-9, lire en ligne)
  • Ralph I. Dorfman, Steroidal Activity in Experimental Animals and Man, Elsevier Science, , 398– (ISBN 978-1-4832-7299-3, lire en ligne)

    « Intramuscular administration of 17α-hydroxyprogesterone caproate produced signs and symptoms of adrenal insufficiency in Addisonians maintained on cortisol and 9α-fluorocortisol (Melby, 1961) and thereby showed properties similar to progesterone and 17α-hydroxyprogesterone. However, further tests will be required to eludicate its pharmacodynamics properties. Contrastingly, there was no evidence for salt dissipation with the test of a smaller dose of the steroid to normal subjects (Landau et al., 1958). »

  • International Agency for Research on Cancer, Sex Hormones (II)., International Agency for Research on Cancer, (ISBN 978-92-832-1221-8, lire en ligne), p. 401

    « 17α-Hydroxyprogesterone caproate was first marketed commercially in Japan in 1954-1955. »

  • Index Nominum 2000 : International Drug Directory, Taylor & Francis, , 532– (ISBN 978-3-88763-075-1, lire en ligne)
  • Donna Shoupe et Daniel R. Mishell, Menopause : Physiology and Pharmacology, Year Book Medical, , 335–351 p. (ISBN 9780815159148, lire en ligne), « Therapeutic Regimens »
  • Benign Prostatic Hypertrophy, Springer Science & Business Media, , 266– (ISBN 978-1-4612-5476-8, lire en ligne)
  • (en) Richard J. Ablin et Malcolm D. Mason, Metastasis of Prostate Cancer, Dordrecht, Netherlands, Springer Science & Business Media, , 286– (ISBN 978-1-4020-5847-9, lire en ligne)
  • Cancer of the Prostate and Kidney, Springer Science & Business Media, , 309, 339 (ISBN 978-1-4684-4349-3, lire en ligne)
  • Prostatic Carcinoma : Biology and Diagnosis, Springer Science & Business Media, , 128– (ISBN 978-94-009-8887-3, lire en ligne)
  • The Treatment of Prostatic Hypertrophy and Neoplasia, Springer Science & Business Media, , 39,132 (ISBN 978-94-015-7190-6, lire en ligne)

    « Geller has also demonstrated significant decreases in plasma or urine testosterone glucuronide levels following the administration of three other anti-androgens. These include Delalutin [hydroxyprogesterone caproate], chlormadinone acetate, and PH-218. It would appear that decreased androgen production is a property shared by all anti-androgens to date. »

  • Jeffrey K. Aronson, Meyler's Side Effects of Endocrine and Metabolic Drugs, Elsevier, , 289– (ISBN 978-0-08-093292-7, lire en ligne)
  • Gianna E. Israel, Donald E. Tarver et Joy Diane Shaffer, Transgender Care : Recommended Guidelines, Practical Information, and Personal Accounts, Temple University Press, , 58– (ISBN 978-1-56639-852-7, lire en ligne)
  • Richard Ekins et Dave King, The Transgender Phenomenon, SAGE Publications, , 48– (ISBN 978-1-84787-726-0, lire en ligne)
  • Richard K. Adler, Sandy Hirsch et Michelle Mordaunt, Voice and Communication Therapy for The Transgender/Transsexual Client : A Comprehensive Clinical Guide, Plural Publishing, , 486– (ISBN 978-1-59756-631-5, lire en ligne)
  • Kenneth L. Becker, Principles and Practice of Endocrinology and Metabolism, Lippincott Williams & Wilkins, , 757–759, 2168 (ISBN 978-0-7817-1750-2, lire en ligne)
  • Sandeep Nema et John D. Ludwig, Pharmaceutical Dosage Forms : Parenteral Medications, Third Edition : Volume 1 : Formulation and Packaging, CRC Press, , 161– (ISBN 978-1-4200-8644-7, lire en ligne)
  • Niels F Muller et Rudolf P Dessing, European Drug Index : European Drug Registrations, CRC Press, , 561– (ISBN 978-3-7692-2114-5, lire en ligne)
  • Freimut A. Leidenberger, Klinische Endokrinologie für Frauenärzte, Springer-Verlag, , 533– (ISBN 978-3-662-08110-5, lire en ligne)
  • Karl Knörr, Fritz K. Beller et Christian Lauritzen, Lehrbuch der Gynäkologie, Springer-Verlag, , 214, 255 (ISBN 978-3-662-00942-0, lire en ligne)
  • Heinrich Kahr, Konservative Therapie der Frauenkrankheiten : Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur, Springer-Verlag, , 22– (ISBN 978-3-7091-5694-0, lire en ligne)
  • Hagers Handbuch der Pharmazeutischen Praxis : Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte und Medizinalbeamte, Springer-Verlag, , 1163– (ISBN 978-3-642-49759-9, lire en ligne)
  • Joachim Ufer, Die Gestagene, Springer-Verlag, , 1026–1124 p. (ISBN 978-3-642-99941-3, DOI 10.1007/978-3-642-99941-3_7, lire en ligne), « Die therapeutische Anwendung der Gestagene beim Menschen »

    « Depotinjektionen [...] 2. Einmalige Injektion von 125mg oder 250mg 17α-Hydroxyprogesteroncapronat als Depotgestagen und 10 mg Oestradiolbenzoat in öliger Lösung (Primosiston) [47, 81, 110, 563, 523, 571, 718, 721, 732, 733, 864, 872, 933, 973, 400]. »

  • Karl Knörr, Henriette Knörr-Gärtner, Fritz K. Beller et Christian Lauritzen, Geburtshilfe und Gynäkologie : Physiologie und Pathologie der Reproduktion, Springer-Verlag, , 583– (ISBN 978-3-642-95583-9, lire en ligne)
  • Benign Prostatic Hypertrophy, Springer Science & Business Media, , 266– (ISBN 978-1-4612-5476-8, lire en ligne)

    « Since the initial report by Geller and associates28 on the use of hydroxyprogesterone caproate in the treatment of BPH, a variety of progestins have been studied in the medical management of this disease: hydroxyprogesterone caproate, chlormadinone acetate,27 and medrogestone (6-methyl-6-dehydro-17-methylprogesterone).50 These drugs should have a beneficial effect in BPH as they inhibit testicular function by suppressing serum LH and have no intrinsic estrogenic or androgenic activity. »

  • Alan J. Wein, Louis R. Kavoussi, Andrew C. Novick, Alan W. Partin et Peters, Campbell-Walsh Urology : Expert Consult Premium Edition : Enhanced Online Features and Print, 4-Volume Set, Elsevier Health Sciences, , 2938– (ISBN 978-1-4160-6911-9, lire en ligne)
  • Eliza B. Geer, The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease : Cushing's Syndrome and Beyond, Springer, , 28– (ISBN 978-3-319-45950-9, lire en ligne)
  • Diane S. Aschenbrenner et Samantha J. Venable, Drug Therapy in Nursing, Lippincott Williams & Wilkins, , 674– (ISBN 978-0-7817-6587-9, lire en ligne)
  • Perry T. Cupps, Reproduction in Domestic Animals, Elsevier, , 101– (ISBN 978-0-08-057109-6, lire en ligne)
  • The Dictionary of Drugs : Chemical Data : Chemical Data, Structures and Bibliographies, Springer, , 664– (ISBN 978-1-4757-2085-3, lire en ligne)
  • Jürgen Engel, Axel Kleemann, Bernhard Kutscher et Dietmar Reichert, Pharmaceutical Substances, 5th Edition, 2009 : Syntheses, Patents and Applications of the most relevant APIs, Thieme, , 677–679 p. (ISBN 978-3-13-179275-4, lire en ligne)
  • William Andrew Publishing, Pharmaceutical Manufacturing Encyclopedia, Elsevier, , 1865–1866 p. (ISBN 978-0-8155-1856-3, lire en ligne)
  • Karl Junkmann, Hedwig Langecker et Leonore Damrosch, Die Gestagene, Springer-Verlag, , 1–44 p. (ISBN 978-3-642-99941-3, DOI 10.1007/978-3-642-99941-3_1, lire en ligne), « Chemie der Gestagene »

    « 3. Hydroxyprogesteron-caproat. C27H4004, Mol.-Gew.: 428,62; chemische Bezeichnung Δ4-Pregnen-17α-ol-3,20-dion-17α-capronat, Trivialnamen: Hydroxyprogesteroncapronat, 17α-Hydroxyprogesteron-17α-capronat. Synthese: [88]. Darstellung: [88]. Eigenschaften: weißes kristallines Pulver (aus Isopropyläther) oder Methanol, F.: 119-122⁰, [α]D: +60⁰ (Chlf.) UV-Absorption: λmax.: 240 mμ, ε = 17000. Dipolmoment: »

  • ACRH, U.S. Dept. of Energy, (lire en ligne), p. 71

    « [The] minimal activity [of 17(a)-hydroxyprogesterone] is magnified to an unexpected degree by the esterification of this steroid with caproic acid to produce 17(a)-hydroxyprogesterone-17-n-caproate, first reported by Karl Junkmann in 1954.6,7 »

  • Ralph Isadore Dorfman, Methods in Hormone Research, Academic Press, (lire en ligne), p. 86

    « Junkmann (1954) reported that the acetate, butyrate, and caproate forms had both increased and prolonged activity, [...] »

  • Norman Applezweig, Steroid Drugs, Blakiston Division, McGraw-Hill, , 101–102 p. (lire en ligne)

    « Junkmann of Schering, AG., however, was able to show that long chain esters of 17a-hydroxyprogesterones such as the 17a-caproate produced powerful long-acting progestational effect. This compound is marketed in the United States as Delalutin by Squibb, and has been heavily used for the treatment of habitual abortion. »

  • New and Nonofficial Drugs, Lippincott, (lire en ligne), p. 662

    « Supplied by.—E. R. Squibb & Sons (Delalutin). Year of introduction: 1956. »

  • Pharmacology of hormones, Thieme, , 248 p. (ISBN 978-3-13-518901-7, lire en ligne), p. 105

    « Progesterone itself is now almost never used for the management of any imminent threat to pregnancy. For oral therapy, it is in any event unsuitable and for injections, it has now been replaced by the long-acting esters of 17α-hydroxyprogesterone. The caproate (Proluton, Delalutin), a long-acting ester, is available in [...] Progesterone is rarely used therapeutically. It has largely been superseded by a long-acting ester of 17α-hydroxyprogesterone, for parenteral therapy. »

  • Antibiotic Medicine and Clinical Therapy, (lire en ligne), p. 249
  • Thomas L. Dao, Antineoplastic and Immunosuppressive Agents, , 170–192 p. (ISBN 978-3-642-65806-8, DOI 10.1007/978-3-642-65806-8_11, lire en ligne), « Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms »

boston.com

doi.org

dx.doi.org

  • « 17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth », Paediatric Drugs, vol. 13, no 5,‎ , p. 337–45 (PMID 21888448, DOI 10.2165/11208140-000000000-00000)
  • « 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth », Clinical Drug Investigation, vol. 33, no 3,‎ , p. 223–7 (PMID 23413110, DOI 10.1007/s40261-013-0060-6)
  • « Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations », Seminars in Perinatology, vol. 38, no 8,‎ , p. 516–22 (PMID 25256193, PMCID 4253874, DOI 10.1053/j.semperi.2014.08.013)
  • « 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going? », Seminars in Perinatology, vol. 41, no 8,‎ , p. 461–467 (PMID 28947068, DOI 10.1053/j.semperi.2017.08.004)
  • « A review of "once-a-month" combined injectable contraceptives », Journal of Obstetrics and Gynaecology, vol. 4 Suppl 1,‎ , S1-34 (PMID 12290848, DOI 10.3109/01443619409027641)
  • « Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats », Xenobiotica; the Fate of Foreign Compounds in Biological Systems, vol. 46, no 2,‎ , p. 169–74 (PMID 26153441, PMCID 4809632, DOI 10.3109/00498254.2015.1057547)
  • « Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice », American Journal of Obstetrics and Gynecology, vol. 208, no 6,‎ , p. 421–6 (PMID 23643669, PMCID 4120746, DOI 10.1016/j.ajog.2013.04.027)
  • « Progesterone therapy in pre-eclamptic toxaemia », Acta Obstetricia et Gynecologica Scandinavica, vol. 54, no 3,‎ , p. 195–202 (PMID 1163210, DOI 10.3109/00016347509157760) :

    « Melby (14) found that when progesterone was administered to patients suffering from the syndrome of idiopathic oedema, they experienced a diuresis, with a high excretion of sodium and water within 24 hours after a single injection of 500 mg of 17-α-hydroxyprogesterone caproate. »

  • « Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function », JAMA, vol. 193, no 2,‎ , p. 121–8 (PMID 14304354, DOI 10.1001/jama.1965.03090020035009)
  • « 17 hydroxyprogesterone for the prevention of preterm delivery », Obstetrics and Gynecology, vol. 105, no 5 Pt 1,‎ , p. 1128–35 (PMID 15863556, DOI 10.1097/01.AOG.0000160432.95395.8f)
  • « Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth », The Journal of Steroid Biochemistry and Molecular Biology, vol. 139,‎ , p. 173–81 (PMID 23410596, DOI 10.1016/j.jsbmb.2013.01.015)
  • « Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP », The New England Journal of Medicine, vol. 364, no 18,‎ , p. 1689–91 (PMID 21410391, DOI 10.1056/NEJMp1102796)
  • « Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate », The New England Journal of Medicine, vol. 348, no 24,‎ , p. 2379–85 (PMID 12802023, DOI 10.1056/NEJMoa035140)
  • « Progesterone and preterm: seventy years of "déjà vu" or "still to be seen"? », Birth, vol. 31, no 3,‎ , p. 230–5 (PMID 15330887, DOI 10.1111/j.0730-7659.2004.00315.x)
  • « Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor », The New England Journal of Medicine, vol. 293, no 14,‎ , p. 675–80 (PMID 1099445, DOI 10.1056/nejm197510022931401)
  • « Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate », American Journal of Obstetrics and Gynecology, vol. 151, no 5,‎ , p. 574–7 (PMID 3976757, DOI 10.1016/0002-9378(85)90141-3)
  • « Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo », Obstetrics and Gynecology, vol. 110, no 4,‎ , p. 865–72 (PMID 17906021, DOI 10.1097/01.AOG.0000281348.51499.bc)
  • « Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate », Teratology, vol. 35, no 1,‎ , p. 129–36 (PMID 3563931, DOI 10.1002/tera.1420350116)
  • « The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population », American Journal of Obstetrics and Gynecology, vol. 146, no 2,‎ , p. 187–90 (PMID 6682631, DOI 10.1016/0002-9378(83)91051-7)
  • (en) « Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial », Lancet, vol. 387, no 10033,‎ , p. 2106–2116 (PMID 26921136, PMCID 5406617, DOI 10.1016/S0140-6736(16)00350-0)
  • Dodd, Grivell, OBrien et Dowswell, « Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. », The Cochrane Database of Systematic Reviews, vol. 2019, no 11,‎ (PMID 31745984, PMCID 6864412, DOI 10.1002/14651858.CD012024.pub3)
  • « Hydroxyprogesterone caproate therapy in advanced endometrial cancer », Cancer, vol. 27, no 3,‎ , p. 485–502 (PMID 5549492, DOI 10.1002/1097-0142(197103)27:3<485::AID-CNCR2820270302>3.0.CO;2-1)
  • (en) J. R. Newton, Catherine D'arcangues et P. E. Hall, « A review of ‘once-a-month's combined injectable contraceptives », Journal of Obstetrics and Gynaecology, vol. 14, no sup1,‎ , s1–s34 (PMID 12290848, DOI 10.3109/01443619409027641, lire en ligne, consulté le )
  • Agostini, Casini, Costabile et Paragona, « Efficacy and safety of 17α-hydroxyprogesterone caproate in hormone replacement therapy », Gynecological Endocrinology, vol. 21, no 5,‎ , p. 265–267 (ISSN 0951-3590, PMID 16373245, DOI 10.1080/09513590500368650)
  • « Status of sex reassignment surgery for gender identity disorder in Japan », International Journal of Urology, vol. 19, no 5,‎ , p. 402–14 (PMID 22372595, DOI 10.1111/j.1442-2042.2012.02975.x)
  • « Altered arterial stiffness in male-to-female transsexuals undergoing hormonal treatment », The Journal of Obstetrics and Gynaecology Research, vol. 38, no 6,‎ , p. 932–40 (PMID 22487218, DOI 10.1111/j.1447-0756.2011.01815.x, lire en ligne)
  • « Pharmacokinetics of once-a-month injectable contraceptives », Contraception, vol. 49, no 4,‎ , p. 347–59 (PMID 8013219, DOI 10.1016/0010-7824(94)90032-9)
  • « Pharmacodynamic effects of once-a-month combined injectable contraceptives », Contraception, vol. 49, no 4,‎ , p. 361–85 (PMID 8013220, DOI 10.1016/0010-7824(94)90033-7)
  • Joachim Ufer, Die Gestagene, Springer-Verlag, , 1026–1124 p. (ISBN 978-3-642-99941-3, DOI 10.1007/978-3-642-99941-3_7, lire en ligne), « Die therapeutische Anwendung der Gestagene beim Menschen »

    « Depotinjektionen [...] 2. Einmalige Injektion von 125mg oder 250mg 17α-Hydroxyprogesteroncapronat als Depotgestagen und 10 mg Oestradiolbenzoat in öliger Lösung (Primosiston) [47, 81, 110, 563, 523, 571, 718, 721, 732, 733, 864, 872, 933, 973, 400]. »

  • « Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7) », Oncology, vol. 47, no 1,‎ , p. 19–24 (PMID 2137212, DOI 10.1159/000226779) :

    « After the transplantation, each mouse received an intramuscular injection of 0.1 ml EP Hormone Depot consisting of 1 mg/ml 17-β-estradiol dipropionate and 50 mg/ml hydroxyprogesterone caproate every week. »

  • « Fertility promoting and inhibiting effects of new steroid hormonal substances », J Am Med Assoc, vol. 169, no 16,‎ , p. 1843–54 (PMID 13640942, DOI 10.1001/jama.1959.03000330015003)
  • « What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? », Obstetrics and Gynecology Clinics of North America, vol. 38, no 2,‎ , p. 235–46, ix–x (PMID 21575799, DOI 10.1016/j.ogc.2011.02.014)
  • (en) « Pharmacology of estrogens and progestogens: influence of different routes of administration », Climacteric, vol. 8 Suppl 1,‎ , p. 3–63 (PMID 16112947, DOI 10.1080/13697130500148875, lire en ligne)
  • « Clinical use of oestrogens and progestogens », Maturitas, vol. 12, no 3,‎ , p. 199–214 (PMID 2215269, DOI 10.1016/0378-5122(90)90004-P)
  • Toppozada MK, « Existing once-a-month combined injectable contraceptives », Contraception, vol. 49, no 4,‎ , p. 293–301 (PMID 8013216, DOI 10.1016/0010-7824(94)90029-9)
  • « Conception control by long-acting progestogens: preliminary report », Obstetrics and Gynecology, vol. 21,‎ , p. 666–8 (PMID 13992789, DOI 10.1097/00006250-196306000-00003, lire en ligne)
  • « The use of progestational agents in obstetrics and gynecology », Clinical Obstetrics and Gynecology, vol. 3, no 4,‎ , p. 1047–67 (PMID 13756432, DOI 10.1097/00003081-196003040-00019) :

    « 50 mg of [medroxyprogesterone acetate], intramuscularly, is equivalent to 250 mg [hydroxyprogesterone caproate] »

  • « Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins », American Journal of Obstetrics and Gynecology, vol. 197, no 6,‎ , p. 599.e1–7 (PMID 18060946, PMCID 2278032, DOI 10.1016/j.ajog.2007.05.024)
  • « Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study », Urology, vol. 9, no 2,‎ , p. 144–8 (PMID 65818, DOI 10.1016/0090-4295(77)90184-4)
  • « Progesterone treatment for local recurrence and metastases in carcinoma corporis uteri », Acta Radiologica, vol. 10, no 2,‎ , p. 187–92 (PMID 5556820, DOI 10.3109/02841867109129755) :

    « The preparations used were Proluton Depot (17a-hydroxy-progesterone caproate) and in 3 patients SH 5132 (17a-hydroxy-19-norprogesterone caproate); 100 mg of the latter corresponds to 1000 mg of Proluton Depot. »

  • « On gestagen treatment of advanced prostatic carcinoma », Scandinavian Journal of Urology and Nephrology, vol. 12, no 2,‎ , p. 119–21 (PMID 694436, DOI 10.3109/00365597809179977)
  • « Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men », Clinical Endocrinology, vol. 11, no 5,‎ , p. 497–504 (PMID 519881, DOI 10.1111/j.1365-2265.1979.tb03102.x) :

    « Another synthetic gestogen, 17-hydroxy-19-norprogesterone caproate (Depostat-Schering), 400 mg by i.m. weekly injections suppressed T levels to 25% of pretreatment values (Sander er al., 1978). »

  • « Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men », The Journal of Clinical Endocrinology and Metabolism, vol. 59, no 5,‎ , p. 963–9 (PMID 6237116, DOI 10.1210/jcem-59-5-963)
  • « Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial », British Journal of Urology, vol. 52, no 3,‎ , p. 208–15 (PMID 7000222, DOI 10.1111/j.1464-410x.1980.tb02961.x)
  • « An endocrine basis for endometrial carcinoma », American Journal of Obstetrics and Gynecology, vol. 77, no 2,‎ , p. 233–42 (PMID 13617315, DOI 10.1016/0002-9378(59)90223-6)
  • « Short-term progestogen treatment of endometrial carcinoma. Histological, histochemical and hormonal studies », Acta Obstetricia et Gynecologica Scandinavica, vol. 51, no 1,‎ , p. 55–62 (PMID 4261828, DOI 10.3109/00016347209154968)
  • « Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening », Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no 12,‎ , p. 4929–34 (PMID 19255438, PMCID 2660744, DOI 10.1073/pnas.0812308106, Bibcode 2009PNAS..106.4929G)
  • « Progestins can mimic, inhibit and potentiate the actions of androgens », Pharmacology & Therapeutics, vol. 23, no 3,‎ , p. 443–59 (PMID 6371845, DOI 10.1016/0163-7258(83)90023-2)
  • Crowley et Macdonald, « Delalutin and estrogens for the treatment of advanced mammary carcinoma in the postmenopausal woman », Cancer, vol. 18, no 4,‎ , p. 436–446 (ISSN 0008-543X, PMID 14278040, DOI 10.1002/1097-0142(196504)18:4<436::AID-CNCR2820180407>3.0.CO;2-D)
  • « The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy », Reproductive Sciences, vol. 16, no 11,‎ , p. 1052–61 (PMID 19602723, DOI 10.1177/1933719109340926)
  • « Non-genomic progesterone actions in female reproduction », Human Reproduction Update, vol. 15, no 1,‎ , p. 119–38 (PMID 18936037, DOI 10.1093/humupd/dmn044)
  • « Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors », Progress in Neurobiology, vol. 113,‎ , p. 6–39 (PMID 24172649, DOI 10.1016/j.pneurobio.2013.09.004)
  • « The importance of 'awareness' for understanding fetal pain », Brain Research. Brain Research Reviews, vol. 49, no 3,‎ , p. 455–71 (PMID 16269314, DOI 10.1016/j.brainresrev.2005.01.006)
  • « The emergence of human consciousness: from fetal to neonatal life », Pediatric Research, vol. 65, no 3,‎ , p. 255–60 (PMID 19092726, DOI 10.1203/PDR.0b013e3181973b0d, lire en ligne) :

    « [...] the fetus is sedated by the low oxygen tension of the fetal blood and the neurosteroid anesthetics pregnanolone and the sleep-inducing prostaglandin D2 provided by the placenta (36). »

  • « Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation », American Journal of Obstetrics and Gynecology, vol. 207, no 5,‎ , p. 398.e1–8 (PMID 22967833, PMCID 3586341, DOI 10.1016/j.ajog.2012.08.015)
  • « Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation », American Journal of Obstetrics and Gynecology, vol. 205, no 1,‎ , p. 40.e1–8 (PMID 21620357, PMCID 3165062, DOI 10.1016/j.ajog.2011.03.028)
  • « Observations of the role of progestational agents in human gynecologic disorders and pregnancy complications », Ann. N. Y. Acad. Sci., vol. 71, no 5,‎ , p. 727–52 (PMID 13583829, DOI 10.1111/j.1749-6632.1958.tb46803.x, Bibcode 1958NYASA..71..727B)
  • « 770: Pharmacokinetics and tolerability of oral 17-hydroxyprogesterone caproate (HPC) relative to intramuscular (IM) HPC. », American Journal of Obstetrics & Gynecology, vol. 212, no 1,‎ , S374 (DOI 10.1016/j.ajog.2014.10.976)
  • « Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy », AJP Reports, vol. 8, no 2,‎ , e106–e112 (PMID 29765789, PMCID 5951785, DOI 10.1055/s-0038-1639331)
  • « Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study », Clinical Therapeutics, vol. 39, no 12,‎ , p. 2345–2354 (PMID 29191450, DOI 10.1016/j.clinthera.2017.10.020)
  • « Steroid-protein interactions. Human corticosteroid binding globulin: some physicochemical properties and binding specificity », Biochemistry, vol. 20, no 21,‎ , p. 6211–8 (PMID 7306509, DOI 10.1021/bi00524a047)
  • « Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma », The Journal of Clinical Endocrinology and Metabolism, vol. 53, no 1,‎ , p. 58–68 (PMID 7195404, DOI 10.1210/jcem-53-1-58)
  • « Treatment of persistent acne in women with 17 alpha hydroxyprogesterone caproate (delalutin); a preliminary report », The Journal of Investigative Dermatology, vol. 31, no 5,‎ , p. 247–50 (PMID 13598928, DOI 10.1038/jid.1958.114)
  • Karl Junkmann, Hedwig Langecker et Leonore Damrosch, Die Gestagene, Springer-Verlag, , 1–44 p. (ISBN 978-3-642-99941-3, DOI 10.1007/978-3-642-99941-3_1, lire en ligne), « Chemie der Gestagene »

    « 3. Hydroxyprogesteron-caproat. C27H4004, Mol.-Gew.: 428,62; chemische Bezeichnung Δ4-Pregnen-17α-ol-3,20-dion-17α-capronat, Trivialnamen: Hydroxyprogesteroncapronat, 17α-Hydroxyprogesteron-17α-capronat. Synthese: [88]. Darstellung: [88]. Eigenschaften: weißes kristallines Pulver (aus Isopropyläther) oder Methanol, F.: 119-122⁰, [α]D: +60⁰ (Chlf.) UV-Absorption: λmax.: 240 mμ, ε = 17000. Dipolmoment: »

  • Junkmann, « Über protrahiert wirksame Gestagene », Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie, vol. 223, no 3,‎ (DOI 10.1007/BF00246995)
  • « Comparative activity of progestational agents on the human endometrium and vaginal epithelium of surgical castrates », Annals of the New York Academy of Sciences, vol. 71, no 5,‎ , p. 599–616 (PMID 13583817, DOI 10.1111/j.1749-6632.1958.tb46791.x, Bibcode 1958NYASA..71..599W) :

    « In the group of new parenteral progestational agents, three substances developed by Karl Junkmann1,2 are the most outstanding and interesting: 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new parenteral progestational agents, 17-ethynyl-19-nortestosterone enanthate, introduced in 1956. »

  • « Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens », Ultrasound in Obstetrics & Gynecology, vol. 42, no 3,‎ , p. 247–53 (PMID 23495199, DOI 10.1002/uog.12456)
  • « The clinical use of monthly injectable contraceptive preparations », Obstetrical & Gynecological Survey, vol. 32, no 6,‎ , p. 335–47 (PMID 865726, DOI 10.1097/00006254-197706000-00001)
  • Thomas L. Dao, Antineoplastic and Immunosuppressive Agents, , 170–192 p. (ISBN 978-3-642-65806-8, DOI 10.1007/978-3-642-65806-8_11, lire en ligne), « Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms »
  • Crowley et Macdonald, « Clinical trial of Delalutin in the treatment of advanced mammary carcinoma in postmenopausal women », Cancer, vol. 15, no 6,‎ , p. 1218–1220 (ISSN 0008-543X, PMID 14024037, DOI 10.1002/1097-0142(196211/12)15:6<1218::AID-CNCR2820150619>3.0.CO;2-Y)
  • Crowley et MacDonald, « Delalutin und Östrogene als Behandlung des vorgeschrittenen Mammakarzinoms bei Frauen nach der Menopause », Gynäkologisch-geburtshilfliche Rundschau, vol. 3, no 4,‎ , p. 271–272 (ISSN 1018-8843, DOI 10.1159/000266855)

drugs.com

egranth.ac.in

krishikosh.egranth.ac.in

  • Santhosh, C. R. (2006). Pharmacokinetics of 17α-Hydroxy Progesterone Caproate in Cattle, Buffalo, Sheep and Goat (Doctoral dissertation, Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar). http://krishikosh.egranth.ac.in/handle/1/68575

fda.gov

accessdata.fda.gov

fda.gov

harvard.edu

ui.adsabs.harvard.edu

  • « Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening », Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no 12,‎ , p. 4929–34 (PMID 19255438, PMCID 2660744, DOI 10.1073/pnas.0812308106, Bibcode 2009PNAS..106.4929G)
  • « Observations of the role of progestational agents in human gynecologic disorders and pregnancy complications », Ann. N. Y. Acad. Sci., vol. 71, no 5,‎ , p. 727–52 (PMID 13583829, DOI 10.1111/j.1749-6632.1958.tb46803.x, Bibcode 1958NYASA..71..727B)
  • « Comparative activity of progestational agents on the human endometrium and vaginal epithelium of surgical castrates », Annals of the New York Academy of Sciences, vol. 71, no 5,‎ , p. 599–616 (PMID 13583817, DOI 10.1111/j.1749-6632.1958.tb46791.x, Bibcode 1958NYASA..71..599W) :

    « In the group of new parenteral progestational agents, three substances developed by Karl Junkmann1,2 are the most outstanding and interesting: 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new parenteral progestational agents, 17-ethynyl-19-nortestosterone enanthate, introduced in 1956. »

heinonline.org

  • (en) « The Orphan Drug Act: How the FDA Unlawfully Usurped Market Exclusivity », Northwestern Journal of Technology and Intellectual Property, Heinonline, vol. 11, no 6,‎ , p. 91, 93 (lire en ligne)

hormonebalance.org

issn.org

portal.issn.org

  • Agostini, Casini, Costabile et Paragona, « Efficacy and safety of 17α-hydroxyprogesterone caproate in hormone replacement therapy », Gynecological Endocrinology, vol. 21, no 5,‎ , p. 265–267 (ISSN 0951-3590, PMID 16373245, DOI 10.1080/09513590500368650)
  • « Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control », World J Pharm Pharm Sci, vol. 3, no 10,‎ , p. 364–392 (ISSN 2278-4357, lire en ligne [archive du ], consulté le )
  • Crowley et Macdonald, « Delalutin and estrogens for the treatment of advanced mammary carcinoma in the postmenopausal woman », Cancer, vol. 18, no 4,‎ , p. 436–446 (ISSN 0008-543X, PMID 14278040, DOI 10.1002/1097-0142(196504)18:4<436::AID-CNCR2820180407>3.0.CO;2-D)
  • Crowley et Macdonald, « Clinical trial of Delalutin in the treatment of advanced mammary carcinoma in postmenopausal women », Cancer, vol. 15, no 6,‎ , p. 1218–1220 (ISSN 0008-543X, PMID 14024037, DOI 10.1002/1097-0142(196211/12)15:6<1218::AID-CNCR2820150619>3.0.CO;2-Y)
  • « Objective remission of metastatic breast carcinoma in a male who received 17-alpha hydroxy progesterone caproate (Delalutin) », Cancer Chemotherapy Reports, vol. 14,‎ , p. 77–81 (ISSN 0069-0112, PMID 13897631)
  • Crowley et MacDonald, « Delalutin und Östrogene als Behandlung des vorgeschrittenen Mammakarzinoms bei Frauen nach der Menopause », Gynäkologisch-geburtshilfliche Rundschau, vol. 3, no 4,‎ , p. 271–272 (ISSN 1018-8843, DOI 10.1159/000266855)
  • (de) « Zur additiven Therapie des metastasierenden Mamma-Karzinoms unter Berücksichtigung des Postmenopausalaltes (Ergebnisse einer randomisierten Studie) », Strahlentherapie, vol. 152, no 3,‎ , p. 235–47 (ISSN 0039-2073, PMID 968923)

lww.com

journals.lww.com

macleans.ca

nih.gov

ncbi.nlm.nih.gov

  • « 17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth », Paediatric Drugs, vol. 13, no 5,‎ , p. 337–45 (PMID 21888448, DOI 10.2165/11208140-000000000-00000)
  • « 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth », Clinical Drug Investigation, vol. 33, no 3,‎ , p. 223–7 (PMID 23413110, DOI 10.1007/s40261-013-0060-6)
  • « Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations », Seminars in Perinatology, vol. 38, no 8,‎ , p. 516–22 (PMID 25256193, PMCID 4253874, DOI 10.1053/j.semperi.2014.08.013)
  • « 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going? », Seminars in Perinatology, vol. 41, no 8,‎ , p. 461–467 (PMID 28947068, DOI 10.1053/j.semperi.2017.08.004)
  • « A review of "once-a-month" combined injectable contraceptives », Journal of Obstetrics and Gynaecology, vol. 4 Suppl 1,‎ , S1-34 (PMID 12290848, DOI 10.3109/01443619409027641)
  • « Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats », Xenobiotica; the Fate of Foreign Compounds in Biological Systems, vol. 46, no 2,‎ , p. 169–74 (PMID 26153441, PMCID 4809632, DOI 10.3109/00498254.2015.1057547)
  • « Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice », American Journal of Obstetrics and Gynecology, vol. 208, no 6,‎ , p. 421–6 (PMID 23643669, PMCID 4120746, DOI 10.1016/j.ajog.2013.04.027)
  • « Progesterone therapy in pre-eclamptic toxaemia », Acta Obstetricia et Gynecologica Scandinavica, vol. 54, no 3,‎ , p. 195–202 (PMID 1163210, DOI 10.3109/00016347509157760) :

    « Melby (14) found that when progesterone was administered to patients suffering from the syndrome of idiopathic oedema, they experienced a diuresis, with a high excretion of sodium and water within 24 hours after a single injection of 500 mg of 17-α-hydroxyprogesterone caproate. »

  • « Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function », JAMA, vol. 193, no 2,‎ , p. 121–8 (PMID 14304354, DOI 10.1001/jama.1965.03090020035009)
  • « 17 hydroxyprogesterone for the prevention of preterm delivery », Obstetrics and Gynecology, vol. 105, no 5 Pt 1,‎ , p. 1128–35 (PMID 15863556, DOI 10.1097/01.AOG.0000160432.95395.8f)
  • « Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth », The Journal of Steroid Biochemistry and Molecular Biology, vol. 139,‎ , p. 173–81 (PMID 23410596, DOI 10.1016/j.jsbmb.2013.01.015)
  • « Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP », The New England Journal of Medicine, vol. 364, no 18,‎ , p. 1689–91 (PMID 21410391, DOI 10.1056/NEJMp1102796)
  • « Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate », The New England Journal of Medicine, vol. 348, no 24,‎ , p. 2379–85 (PMID 12802023, DOI 10.1056/NEJMoa035140)
  • « Progesterone and preterm: seventy years of "déjà vu" or "still to be seen"? », Birth, vol. 31, no 3,‎ , p. 230–5 (PMID 15330887, DOI 10.1111/j.0730-7659.2004.00315.x)
  • « Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor », The New England Journal of Medicine, vol. 293, no 14,‎ , p. 675–80 (PMID 1099445, DOI 10.1056/nejm197510022931401)
  • « Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate », American Journal of Obstetrics and Gynecology, vol. 151, no 5,‎ , p. 574–7 (PMID 3976757, DOI 10.1016/0002-9378(85)90141-3)
  • « Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo », Obstetrics and Gynecology, vol. 110, no 4,‎ , p. 865–72 (PMID 17906021, DOI 10.1097/01.AOG.0000281348.51499.bc)
  • « Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate », Teratology, vol. 35, no 1,‎ , p. 129–36 (PMID 3563931, DOI 10.1002/tera.1420350116)
  • « The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population », American Journal of Obstetrics and Gynecology, vol. 146, no 2,‎ , p. 187–90 (PMID 6682631, DOI 10.1016/0002-9378(83)91051-7)
  • (en) « Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial », Lancet, vol. 387, no 10033,‎ , p. 2106–2116 (PMID 26921136, PMCID 5406617, DOI 10.1016/S0140-6736(16)00350-0)
  • Dodd, Grivell, OBrien et Dowswell, « Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. », The Cochrane Database of Systematic Reviews, vol. 2019, no 11,‎ (PMID 31745984, PMCID 6864412, DOI 10.1002/14651858.CD012024.pub3)
  • « Hydroxyprogesterone caproate therapy in advanced endometrial cancer », Cancer, vol. 27, no 3,‎ , p. 485–502 (PMID 5549492, DOI 10.1002/1097-0142(197103)27:3<485::AID-CNCR2820270302>3.0.CO;2-1)
  • (en) J. R. Newton, Catherine D'arcangues et P. E. Hall, « A review of ‘once-a-month's combined injectable contraceptives », Journal of Obstetrics and Gynaecology, vol. 14, no sup1,‎ , s1–s34 (PMID 12290848, DOI 10.3109/01443619409027641, lire en ligne, consulté le )
  • Agostini, Casini, Costabile et Paragona, « Efficacy and safety of 17α-hydroxyprogesterone caproate in hormone replacement therapy », Gynecological Endocrinology, vol. 21, no 5,‎ , p. 265–267 (ISSN 0951-3590, PMID 16373245, DOI 10.1080/09513590500368650)
  • « Status of sex reassignment surgery for gender identity disorder in Japan », International Journal of Urology, vol. 19, no 5,‎ , p. 402–14 (PMID 22372595, DOI 10.1111/j.1442-2042.2012.02975.x)
  • « Altered arterial stiffness in male-to-female transsexuals undergoing hormonal treatment », The Journal of Obstetrics and Gynaecology Research, vol. 38, no 6,‎ , p. 932–40 (PMID 22487218, DOI 10.1111/j.1447-0756.2011.01815.x, lire en ligne)
  • « Pharmacokinetics of once-a-month injectable contraceptives », Contraception, vol. 49, no 4,‎ , p. 347–59 (PMID 8013219, DOI 10.1016/0010-7824(94)90032-9)
  • « Pharmacodynamic effects of once-a-month combined injectable contraceptives », Contraception, vol. 49, no 4,‎ , p. 361–85 (PMID 8013220, DOI 10.1016/0010-7824(94)90033-7)
  • « Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7) », Oncology, vol. 47, no 1,‎ , p. 19–24 (PMID 2137212, DOI 10.1159/000226779) :

    « After the transplantation, each mouse received an intramuscular injection of 0.1 ml EP Hormone Depot consisting of 1 mg/ml 17-β-estradiol dipropionate and 50 mg/ml hydroxyprogesterone caproate every week. »

  • « Fertility promoting and inhibiting effects of new steroid hormonal substances », J Am Med Assoc, vol. 169, no 16,‎ , p. 1843–54 (PMID 13640942, DOI 10.1001/jama.1959.03000330015003)
  • « What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? », Obstetrics and Gynecology Clinics of North America, vol. 38, no 2,‎ , p. 235–46, ix–x (PMID 21575799, DOI 10.1016/j.ogc.2011.02.014)
  • (en) « Pharmacology of estrogens and progestogens: influence of different routes of administration », Climacteric, vol. 8 Suppl 1,‎ , p. 3–63 (PMID 16112947, DOI 10.1080/13697130500148875, lire en ligne)
  • « Clinical use of oestrogens and progestogens », Maturitas, vol. 12, no 3,‎ , p. 199–214 (PMID 2215269, DOI 10.1016/0378-5122(90)90004-P)
  • Toppozada MK, « Existing once-a-month combined injectable contraceptives », Contraception, vol. 49, no 4,‎ , p. 293–301 (PMID 8013216, DOI 10.1016/0010-7824(94)90029-9)
  • « Conception control by long-acting progestogens: preliminary report », Obstetrics and Gynecology, vol. 21,‎ , p. 666–8 (PMID 13992789, DOI 10.1097/00006250-196306000-00003, lire en ligne)
  • « The use of progestational agents in obstetrics and gynecology », Clinical Obstetrics and Gynecology, vol. 3, no 4,‎ , p. 1047–67 (PMID 13756432, DOI 10.1097/00003081-196003040-00019) :

    « 50 mg of [medroxyprogesterone acetate], intramuscularly, is equivalent to 250 mg [hydroxyprogesterone caproate] »

  • « Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins », American Journal of Obstetrics and Gynecology, vol. 197, no 6,‎ , p. 599.e1–7 (PMID 18060946, PMCID 2278032, DOI 10.1016/j.ajog.2007.05.024)
  • (zh) « [Changes in reproductive hormones levels in the treatment of endometrial precancerous lesion with hydroxyprogesterone caproate] », Zhonghua Fu Chan Ke Za Zhi, vol. 29, no 4,‎ , p. 205–6, 251 (PMID 8082440) :

    « In this paper, 14 cases of precancerous lesion of endometrium were treated with hydroxyprogesterone caproate and a series of hormone determination was analysed before and after treatment. Results showed that LH and LH/FSH were dramatically decreased. (LH P < 0.05, LH/FSH P < 0.01). »

  • « Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study », Urology, vol. 9, no 2,‎ , p. 144–8 (PMID 65818, DOI 10.1016/0090-4295(77)90184-4)
  • « Effect of progestational agents on carcinoma of the prostate », Cancer Chemother Rep, vol. 51, no 1,‎ , p. 41–6 (PMID 6039663)
  • « Progesterone treatment for local recurrence and metastases in carcinoma corporis uteri », Acta Radiologica, vol. 10, no 2,‎ , p. 187–92 (PMID 5556820, DOI 10.3109/02841867109129755) :

    « The preparations used were Proluton Depot (17a-hydroxy-progesterone caproate) and in 3 patients SH 5132 (17a-hydroxy-19-norprogesterone caproate); 100 mg of the latter corresponds to 1000 mg of Proluton Depot. »

  • « On gestagen treatment of advanced prostatic carcinoma », Scandinavian Journal of Urology and Nephrology, vol. 12, no 2,‎ , p. 119–21 (PMID 694436, DOI 10.3109/00365597809179977)
  • « Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men », Clinical Endocrinology, vol. 11, no 5,‎ , p. 497–504 (PMID 519881, DOI 10.1111/j.1365-2265.1979.tb03102.x) :

    « Another synthetic gestogen, 17-hydroxy-19-norprogesterone caproate (Depostat-Schering), 400 mg by i.m. weekly injections suppressed T levels to 25% of pretreatment values (Sander er al., 1978). »

  • « Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men », The Journal of Clinical Endocrinology and Metabolism, vol. 59, no 5,‎ , p. 963–9 (PMID 6237116, DOI 10.1210/jcem-59-5-963)
  • « Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial », British Journal of Urology, vol. 52, no 3,‎ , p. 208–15 (PMID 7000222, DOI 10.1111/j.1464-410x.1980.tb02961.x)
  • « An endocrine basis for endometrial carcinoma », American Journal of Obstetrics and Gynecology, vol. 77, no 2,‎ , p. 233–42 (PMID 13617315, DOI 10.1016/0002-9378(59)90223-6)
  • « Short-term progestogen treatment of endometrial carcinoma. Histological, histochemical and hormonal studies », Acta Obstetricia et Gynecologica Scandinavica, vol. 51, no 1,‎ , p. 55–62 (PMID 4261828, DOI 10.3109/00016347209154968)
  • « Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening », Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no 12,‎ , p. 4929–34 (PMID 19255438, PMCID 2660744, DOI 10.1073/pnas.0812308106, Bibcode 2009PNAS..106.4929G)
  • « Progestins can mimic, inhibit and potentiate the actions of androgens », Pharmacology & Therapeutics, vol. 23, no 3,‎ , p. 443–59 (PMID 6371845, DOI 10.1016/0163-7258(83)90023-2)
  • Crowley et Macdonald, « Delalutin and estrogens for the treatment of advanced mammary carcinoma in the postmenopausal woman », Cancer, vol. 18, no 4,‎ , p. 436–446 (ISSN 0008-543X, PMID 14278040, DOI 10.1002/1097-0142(196504)18:4<436::AID-CNCR2820180407>3.0.CO;2-D)
  • « The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy », Reproductive Sciences, vol. 16, no 11,‎ , p. 1052–61 (PMID 19602723, DOI 10.1177/1933719109340926)
  • « Non-genomic progesterone actions in female reproduction », Human Reproduction Update, vol. 15, no 1,‎ , p. 119–38 (PMID 18936037, DOI 10.1093/humupd/dmn044)
  • « Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors », Progress in Neurobiology, vol. 113,‎ , p. 6–39 (PMID 24172649, DOI 10.1016/j.pneurobio.2013.09.004)
  • « The importance of 'awareness' for understanding fetal pain », Brain Research. Brain Research Reviews, vol. 49, no 3,‎ , p. 455–71 (PMID 16269314, DOI 10.1016/j.brainresrev.2005.01.006)
  • « The emergence of human consciousness: from fetal to neonatal life », Pediatric Research, vol. 65, no 3,‎ , p. 255–60 (PMID 19092726, DOI 10.1203/PDR.0b013e3181973b0d, lire en ligne) :

    « [...] the fetus is sedated by the low oxygen tension of the fetal blood and the neurosteroid anesthetics pregnanolone and the sleep-inducing prostaglandin D2 provided by the placenta (36). »

  • « Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation », American Journal of Obstetrics and Gynecology, vol. 207, no 5,‎ , p. 398.e1–8 (PMID 22967833, PMCID 3586341, DOI 10.1016/j.ajog.2012.08.015)
  • « Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation », American Journal of Obstetrics and Gynecology, vol. 205, no 1,‎ , p. 40.e1–8 (PMID 21620357, PMCID 3165062, DOI 10.1016/j.ajog.2011.03.028)
  • « Observations of the role of progestational agents in human gynecologic disorders and pregnancy complications », Ann. N. Y. Acad. Sci., vol. 71, no 5,‎ , p. 727–52 (PMID 13583829, DOI 10.1111/j.1749-6632.1958.tb46803.x, Bibcode 1958NYASA..71..727B)
  • (de) « Die perorale wirksamkeit synthetischer gestagene », Zentralbl Gynakol, vol. 79, no 14,‎ , p. 529–39 (PMID 13443471)
  • « Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy », AJP Reports, vol. 8, no 2,‎ , e106–e112 (PMID 29765789, PMCID 5951785, DOI 10.1055/s-0038-1639331)
  • « Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study », Clinical Therapeutics, vol. 39, no 12,‎ , p. 2345–2354 (PMID 29191450, DOI 10.1016/j.clinthera.2017.10.020)
  • « Steroid-protein interactions. Human corticosteroid binding globulin: some physicochemical properties and binding specificity », Biochemistry, vol. 20, no 21,‎ , p. 6211–8 (PMID 7306509, DOI 10.1021/bi00524a047)
  • « Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma », The Journal of Clinical Endocrinology and Metabolism, vol. 53, no 1,‎ , p. 58–68 (PMID 7195404, DOI 10.1210/jcem-53-1-58)
  • « Treatment of persistent acne in women with 17 alpha hydroxyprogesterone caproate (delalutin); a preliminary report », The Journal of Investigative Dermatology, vol. 31, no 5,‎ , p. 247–50 (PMID 13598928, DOI 10.1038/jid.1958.114)
  • « Comparative activity of progestational agents on the human endometrium and vaginal epithelium of surgical castrates », Annals of the New York Academy of Sciences, vol. 71, no 5,‎ , p. 599–616 (PMID 13583817, DOI 10.1111/j.1749-6632.1958.tb46791.x, Bibcode 1958NYASA..71..599W) :

    « In the group of new parenteral progestational agents, three substances developed by Karl Junkmann1,2 are the most outstanding and interesting: 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new parenteral progestational agents, 17-ethynyl-19-nortestosterone enanthate, introduced in 1956. »

  • « Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens », Ultrasound in Obstetrics & Gynecology, vol. 42, no 3,‎ , p. 247–53 (PMID 23495199, DOI 10.1002/uog.12456)
  • « The clinical use of monthly injectable contraceptive preparations », Obstetrical & Gynecological Survey, vol. 32, no 6,‎ , p. 335–47 (PMID 865726, DOI 10.1097/00006254-197706000-00001)
  • Crowley et Macdonald, « Clinical trial of Delalutin in the treatment of advanced mammary carcinoma in postmenopausal women », Cancer, vol. 15, no 6,‎ , p. 1218–1220 (ISSN 0008-543X, PMID 14024037, DOI 10.1002/1097-0142(196211/12)15:6<1218::AID-CNCR2820150619>3.0.CO;2-Y)
  • « Objective remission of metastatic breast carcinoma in a male who received 17-alpha hydroxy progesterone caproate (Delalutin) », Cancer Chemotherapy Reports, vol. 14,‎ , p. 77–81 (ISSN 0069-0112, PMID 13897631)
  • (de) « Zur additiven Therapie des metastasierenden Mamma-Karzinoms unter Berücksichtigung des Postmenopausalaltes (Ergebnisse einer randomisierten Studie) », Strahlentherapie, vol. 152, no 3,‎ , p. 235–47 (ISSN 0039-2073, PMID 968923)

okayama-u.ac.jp

ousar.lib.okayama-u.ac.jp

philpapers.org

  • « The emergence of human consciousness: from fetal to neonatal life », Pediatric Research, vol. 65, no 3,‎ , p. 255–60 (PMID 19092726, DOI 10.1203/PDR.0b013e3181973b0d, lire en ligne) :

    « [...] the fetus is sedated by the low oxygen tension of the fetal blood and the neurosteroid anesthetics pregnanolone and the sleep-inducing prostaglandin D2 provided by the placenta (36). »

raps.org

scholar.google.com

  • Mokhtar K. Toppozada, Long-Acting Contraception, , 93–103 p. (OCLC 35018604, lire en ligne), « Monthly Injectable Contraceptives »

springer.com

adisinsight.springer.com

tandfonline.com

  • (en) J. R. Newton, Catherine D'arcangues et P. E. Hall, « A review of ‘once-a-month's combined injectable contraceptives », Journal of Obstetrics and Gynaecology, vol. 14, no sup1,‎ , s1–s34 (PMID 12290848, DOI 10.3109/01443619409027641, lire en ligne, consulté le )

web.archive.org

wjpps.com

  • « Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control », World J Pharm Pharm Sci, vol. 3, no 10,‎ , p. 364–392 (ISSN 2278-4357, lire en ligne [archive du ], consulté le )

worldcat.org

  • Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents, vol. II, Pergamon Press, , 245–273 p. (ISBN 978-0080168128, OCLC 278011135), « Orally Active Progestational Compounds. Human Studies: Effects on the Utero-Vaginal Tract »
  • Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents, vol. II, Pergamon Press, , 13–24 p. (ISBN 978-0080168128, OCLC 278011135), « Effects, Duration of Action and Metabolism in Man »
  • Mokhtar K. Toppozada, Long-Acting Contraception, , 93–103 p. (OCLC 35018604, lire en ligne), « Monthly Injectable Contraceptives »